FDA Advisory Committee Votes to Co-Prescribe Naloxone With Opioids

December 19, 2018

A U.S. Food and Drug Administration (FDA) advisory committee voted to include labeling language that recommends co-prescription of naloxone for all or some patients prescribed opioids, according to a news report from the Regulatory Affairs Professionals Society.

The meeting was between the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM).

Read more from the Regulatory Affairs Professionals Society.